ORKA: ORKA-001 achieved 61% PASI 100 at Week 16; Phase 3 is planned for 1H 2027

What happened

In the EVERLAST-B trial, high-dose ORKA-001 helped 61% of patients reach PASI 100 at Week 16, a complete clearing of skin symptoms, versus 0% with placebo. Also, 86% reached PASI 90 and IGA 0/1, and safety matched the IL-23p19 class.

Confirmed

Global impact / market context

Strong skin-clearing results could make ORKA-001 more competitive in psoriasis treatment, a market where patients and doctors value complete clearance. If Phase 3 confirms these findings, Oruka could win share, support pricing, and attract partners or investors funding later development.

Analyst inference

The placebo comparison of 61% versus 0% signals a large treatment effect, though the trial size and design are not given. Phase 3, planned for the first half of 2027, is the costly stage that will test whether these results hold in more patients.

Analyst inference

What to watch

1. Phase 3 is planned for the first half of 2027, pending regulatory discussions, which means talks with regulators about trial design before the larger study begins. Confirmed
2. Watch whether Phase 3 repeats the 61% PASI 100 result in a larger group, since smaller trial results can shrink and change the commercial outlook. Analyst inference
3. Watch company spending on the Phase 3 program, because large trials raise costs and cash needs before any product revenue arrives. Analyst inference

Evidence

• Original source link unavailable